Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB04884_nanopub.RAC7CMRGDXo2BzESNVdilzVv_z6ytrIjWZvB_2dDqM00U#assertion>. }
Showing items 1 to 17 of
17
with 100 items per page.
- drugbank:DB04884 type drugbank_vocabulary:Drug assertion.
- drugbank:DB04884 label "Dapoxetine [drugbank:DB04884]" assertion.
- drugbank:DB04884 seeAlso DB04884 assertion.
- drugbank:DB04884 description "Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions." assertion.
- drugbank:DB04884 identifier "drugbank:DB04884" assertion.
- drugbank:DB04884 title "Dapoxetine" assertion.
- drugbank:DB04884 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:14849767 assertion.
- drugbank:DB04884 drugbank_vocabulary:x-pubchemcompound pubchem.compound:71353 assertion.
- drugbank:DB04884 drugbank_vocabulary:x-chemspider chemspider:64453 assertion.
- drugbank:DB04884 drugbank_vocabulary:x-cas cas:119356-77-3 assertion.
- drugbank:DB04884 drugbank_vocabulary:drugbank-id "DB04884" assertion.
- drugbank:DB04884 bio2rdf_vocabulary:x-identifiers.org DB04884 assertion.
- drugbank:DB04884 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB04884" assertion.
- drugbank:DB04884 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB04884 bio2rdf_vocabulary:identifier "DB04884" assertion.
- drugbank:DB04884 drugbank_vocabulary:x-wikipedia wikipedia:Dapoxetine assertion.
- drugbank:DB04884 drugbank_vocabulary:x-kegg kegg:D03649 assertion.